Research programme: disulfide rich peptides - Protagonist Therapeutics

Drug Profile

Research programme: disulfide rich peptides - Protagonist Therapeutics

Alternative Names: Hepcidin agonists - Protagonist Therapeutics; Interleukin-23 receptor antagonist - Protagonist Therapeutics; Nav1.7 voltage gated sodium channel modulators - Protagonist Thearapeutics

Latest Information Update: 05 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protagonist Therapeutics
  • Class Disulfides; Peptides
  • Mechanism of Action Interleukin-23 receptor antagonists; Nav1.7-voltage-gated-sodium-channel-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases
  • No development reported Neuropathic pain

Most Recent Events

  • 24 May 2017 Protagonist Therapeutics receives SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases for IL-23 agonist development in Irritable bowel disease
  • 12 May 2017 No development reported - Preclinical for Neuropathic pain in USA (Parenteral)
  • 24 Sep 2015 Protagonist Therapeutics receives SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases for IL-23 agonist development in Irritable bowel disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top